Citius Pharmaceuticals (NASDAQ:CTXR) Receives “Hold” Rating from D. Boral Capital

D. Boral Capital reiterated their hold rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research report report published on Friday,Benzinga reports.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Stock Performance

Shares of CTXR stock opened at $0.13 on Friday. Citius Pharmaceuticals has a 1 year low of $0.11 and a 1 year high of $1.07. The stock has a fifty day moving average of $0.40 and a two-hundred day moving average of $0.58. The firm has a market capitalization of $24.18 million, a PE ratio of -0.56 and a beta of 1.66.

Shares of Citius Pharmaceuticals are going to reverse split before the market opens on Tuesday, November 26th. The 1-25 reverse split was announced on Friday, November 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 25th.

Hedge Funds Weigh In On Citius Pharmaceuticals

A number of institutional investors have recently bought and sold shares of CTXR. Point72 DIFC Ltd acquired a new position in shares of Citius Pharmaceuticals in the second quarter worth about $29,000. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals in the 3rd quarter valued at approximately $47,000. Virtu Financial LLC acquired a new position in Citius Pharmaceuticals in the 3rd quarter worth approximately $50,000. Miller Investment Management LP grew its position in Citius Pharmaceuticals by 99.3% during the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Citius Pharmaceuticals during the 2nd quarter valued at $69,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.